SYRE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SYRE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).
Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Spyre Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.
For the Biotechnology subindustry, Spyre Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Margin of Safety % (DCF FCF Based) falls into.
Thank you for viewing the detailed overview of Spyre Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Heidy King-jones | officer: See Remarks | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Fairmount Healthcare Co-invest L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Peter Evan Harwin | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Funds Management Llc | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Cameron Turtle | officer: Chief Operating Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104 |
Michael Thomas Henderson | director | 421 KIPLING STREET, PALO ALTO CA 94301 |
Fairmount Healthcare Fund L.p. | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Ii L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Tomas Kiselak | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Jeff Marc Goldberg | director, officer: President and CEO | C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142 |
Linda L Neuman | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
James Paul Kastenmayer | officer: Interim CEO & General Counsel | ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879 |
Hanley Jr. Michael Conick | officer: Chief Commercial Officer | C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746 |
From GuruFocus
By PRNewswire • 11-01-2024
By PRNewswire • 11-07-2024
By GuruFocus News • 11-15-2024
By GuruFocus News • 01-13-2025
By PRNewswire • 01-22-2025
By PRNewswire • 11-25-2024
By PRNewswire • 01-02-2025
By PRNewswire • 12-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.